The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Abstract
PURPOSE: The present study attempted to identify characteristics that correlated with clinical response to interleukin (IL)-2 therapy in patients with metastatic melanoma. PATIENTS AND METHODS: We retrospectively evaluated laboratory and clinical characteristics of 374 consecutive patients with metastatic melanoma treated with high-dose intravenous bolus IL-2 (720,000 IU/kg) from July 1, 1988, to December 31, 1999, at the Surgery Branch of the National Cancer Institute. RESULTS: The overall objective response rate was 15.5%. Pretreatment parameters such as patient demographics, laboratory values, and prior therapy did not correlate with response; however, 53.6% of patients with only subcutaneous and/or cutaneous metastases responded, compared with 12.4% of patients with disease at other sites (P 2= .000001). During therapy, patients who were responders tended to have received more doses during course 1 (16.2 ± 0.3 doses v 14.5 ± 0.2 doses; P 2= .0095); however, when limited to patients who were able to complete both cycles of course 1, there was no statistically significant difference (P 2= .27). Responders had a higher maximum lymphocyte count immediately after therapy compared with nonresponders (P 2= .0026). The development of abnormal thyroid function tests and vitiligo after therapy was associated with response (thyroid-stimulating hormone, P 2= .01; free T4, P 2= .0049; vitiligo, P 2< 10−6), although thyroid dysfunction may have been related more to the length of IL-2 therapy than to response. CONCLUSION: The presence of metastases only to subcutaneous and/or cutaneous sites, lymphocytosis immediately after treatment, and long-term immunologic side effects, especially vitiligo, were associated with antitumor response to IL-2 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Self-citationRosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Self-citationRosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Self-citationRosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
Self-citationLotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A. Y., Custer, M. C., & Rosenberg, S. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2865 · Cited by 613
Self-citationAtkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Self-citationRosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 485
Self-citationMalignant melanoma: prevention, early detection, and treatment in the 21st century
Rigel, D. S., & Carucci, J. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.4.215 · Cited by 461
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay, J., Négrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., & Jf, M. (1992) · PubMed · Cited by 420
Vitiligo in Patients with Melanoma: Normal Tissue Antigens Can Be Targets for Cancer Immunotherapy
Rosenberg, S. A., & White, D. E. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199601000-00009 · Cited by 333
Self-citationVitiligo in patients with metastatic melanoma: A good prognostic sign
Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M., & Lerner, A. B. (1983) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(83)70182-9 · Cited by 288
Kammula, U. S., White, D. E., & Rosenberg, S. A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980815)83:4<797::aid-cncr25>3.0.co;2-m · Cited by 200
Self-citationPrognostic significance of hypopigmentation in malignant melanoma
Bystryn, J. ‐. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.8.1053 · Cited by 176
Prognostic Significance of Hypopigmentation in Malignant Melanoma
Bystryn, J.-C. (1987) · Archives of Dermatology · doi:10.1001/archderm.1987.01660320095019 · Cited by 171
Tartour, É., Blay, J., Dorval, T., Escudier, B. J., Mosseri, V., Douillard, J., Deneux, L., Gorin, I., Négrier, S., Mathiot, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1697 · Cited by 98
Krouse, R. S., Royal, R. E., Heywood, G., Weintraub, B. D., White, D. E., Steinberg, S. M., Rosenberg, S. A., & Schwartzentruber, D. J. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199511000-00008 · Cited by 94
Self-citationVitiligo and Cutaneous Melanoma
Schallreuter, K. U., Levenig, C., & Berger, J. (2009) · Dermatologica · doi:10.1159/000247693 · Cited by 92
Thyroid dysfunction associated with immunotherapy for patients with cancer
Schwartzentruber, D. J., White, D. E., ZWEIG, M. H., Weintraub, B. D., & Rosenberg, S. A. (1991) · Cancer · doi:10.1002/1097-0142(19911201)68:11<2384::aid-cncr2820681109>3.0.co;2-a · Cited by 74
Self-citationCorrelates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
Royal, R. E., Steinberg, S. M., Krouse, R. S., Heywood, G., White, D. E., Hwu, P., Marincola, F. M., Parkinson, D. R., Schwartzentruber, D. J., Topalian, S. L., et al. (1996) · PubMed · Cited by 70
Self-citationMacfarlane, M., Yang, J. C., Guleria, A. S., White, R. L., Seipp, C. A., Einhorn, J. H., White, D. E., & Rosenberg, S. A. (1995) · Cancer · doi:10.1002/1097-0142(19950215)75:4<1030::aid-cncr2820750420>3.0.co;2-5 · Cited by 49
Self-citationChang, E., & Rosenberg, S. A. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200101000-00010 · Cited by 45
Self-citationKruit, W. H. J., Bolhuis, R. L. H., Goey, S. H., Jansen, R. L. H., Eggermont, A. M. M., Batchelor, D., Schmitz, P. I. M., & Stoter, G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.921 · Cited by 30
Cited by
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationRandomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Self-citationYang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
“Other examples of such an association have been described with IL-2 therapy where vitiligo and hypothyroidism are associated with improved tumor response rates.(18,19) In allotransplantation for renal cancer and leukemia, patients showing graft-versus-host disease have improved therapeutic outcomes, presumably due to…”
BackgroundSelf-citationHua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Self-citation
Metadata
- Authors
- Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., & Rosenberg, S. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-08-01
- Volume
- 19
- Issue
- 15
- Pages
- 3477-3482
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1823669223
- Cited by
- 302
- References
- 25
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.